31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients

"Abstract 31P-magnetic resonance spectroscopy (31P-MRS). is a non-invasive tool to study high-energy phosphate. (HEP) metabolism. We evaluate whether 31P-MRS can. detect early changes in kidney HEP metabolism during a. 6-month trial with Valsartan. Twenty consecutive stable. and normotensive kidney-transplanted patients were. enrolled. Nine of them received short-term low-dose Valsartan. treatment (80 mg\/day) for 6 months, while 11 controls. received no medication. Kidney HEP metabolism was. evaluated both at baseline and after treatment by 31P-MRS. with a 1.5 T system (Gyroscan Intera Master 1.5 MR. System; Philips Medical Systems, Best, The Netherlands).. Valsartan-treated patients (n = 9) showed a significant. increase in b-ATP\/Pi ratio, a marker of kidney HEP. metabolism (baseline = 1.03 ± 0.08 vs. 6 months = 1.26 ±. 0.07, p = 0.03). In contrast, the b-ATP\/Pi ratio in the control. group (n = 11) did not change (baseline = 0.85 ± 0.10. vs. 6 months = 0.89 ± 0.08, ns). The improvement in the. b-ATP\/Pi ratio was not associated with a reduction in arterial. blood pressure or in urinary albumin excretion. Kidneylocalized. 31P-MRS can detect early changes in kidney HEP. metabolism during a short-term low-dose Valsartan treatment. in stable normotensive kidney-transplanted patients"